Thompson Andrew M, Bonnet Muriel, Lee Ho H, Franzblau Scott G, Wan Baojie, Wong George S, Cooper Christopher B, Denny William A
Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612, United States.
ACS Med Chem Lett. 2017 Nov 13;8(12):1275-1280. doi: 10.1021/acsmedchemlett.7b00356. eCollection 2017 Dec 14.
A published study of structural features associated with the aerobic and anaerobic activities of 4- and 5-nitroimidazoles had found that the 3-nitro isomer of pretomanid, , displayed interesting potencies, including against nitroreductase mutant . However, recent nuclear magnetic resonance analyses of two trace byproducts, isolated from early process optimization studies toward a large-scale synthesis of pretomanid, raised structural assignment queries, particularly for , stimulating further investigation. Following our discovery that the reported compound was a 6-nitroimidazooxazole derivative, we developed a synthesis of authentic via nitration of the chiral des-nitro imidazooxazine alcohol in trifluoroacetic or acetic anhydride, and verified its identity through an X-ray crystal structure. Unfortunately, displayed no antitubercular activity (MICs > 128 μM), whereas the second byproduct (3'-methyl pretomanid) was eight-fold more potent than pretomanid in the aerobic assay. These findings further clarify target specificities for bicyclic nitroimidazoles, which may become important in the event of any future clinical resistance.
一项已发表的关于与4-和5-硝基咪唑的需氧和厌氧活性相关的结构特征的研究发现,前托马尼德的3-硝基异构体显示出有趣的效力,包括对硝基还原酶突变体的效力。然而,最近从早期大规模合成前托马尼德的工艺优化研究中分离出的两种痕量副产物的核磁共振分析提出了结构归属问题,特别是对于,这促使进一步研究。在我们发现报道的化合物是6-硝基咪唑并恶唑衍生物之后,我们通过在手性去硝基咪唑并恶嗪醇在三氟乙酸或乙酸酐中硝化来开发一种真实的的合成方法,并通过X射线晶体结构验证了其身份。不幸的是,没有显示出抗结核活性(最低抑菌浓度>128μM),而第二种副产物(3'-甲基前托马尼德)在需氧试验中的效力比前托马尼德高八倍。这些发现进一步阐明了双环硝基咪唑的靶点特异性,这在未来任何临床耐药情况下可能变得很重要。